Ascites as a Predictive Factor in Malignancies in the Last Year of Life–Comparison Between Different Cancer Types
- 23 October 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Palliative Medicine
Abstract
Background: Ascites in malignancies is usually associated with poor prognosis, but the predictive value may vary between different cancer types. Objectives: The aim was to map the frequency and temporal pattern of paracentesis in patients with malignancies in relation to time to death and to evaluate the occurrence of ascites as a predictive factor in different cancer types, with a limitation to the last year of life. Design: A retrospective study based on registry data covering all care visits in the Stockholm Region, Sweden, for seven years was performed. All deceased subjects that had at least one registered paracentesis in the last year of life were included. Results: Of 23,056 subjects dying from cancer, 1863 had undergone paracentesis in the last year of life (8.0%). Ascites requiring paracentesis was most frequently seen in appendiceal cancer (38%), ovarian cancer (35%), cholangiocarcinoma (26%), hepatocellular carcinoma (19%), and pancreatic cancer (17%). The median time for the first paracentesis in all cancer types varied between 248 and 20 days before death. For ovarian cancer, the median time for first paracentesis differed significantly compared with upper gastro-intestinal (GI) cancers, 81 days compared with 30 days (p < 0.0001). Ascites in prostate cancer was rare,1.9%, but when present, a pronounced increase in the frequency of paracentesis was observed in the last three months of life. Conclusion: The occurrence of paracentesis in patients with advanced cancer is generally a sign that death is approaching within the coming months, especially in upper GI cancer. For ovarian and appendiceal cancers, ascites is less useful as a predictive tool.Keywords
This publication has 25 references indexed in Scilit:
- Prognosticators of survival in patients with metastatic pancreatic cancer and ascitesESMO Open, 2023
- Malignant ascites: Current therapy options and treatment prospectsCancer Treatment Reviews, 2023
- Clinical risk factors for ascites in metastatic pancreatic cancerESMO Open, 2023
- A Palliative Approach to Management of Peritoneal Carcinomatosis and Malignant AscitesSurgical Oncology Clinics of North America, 2021
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, ItalyJAMA Internal Medicine, 2020
- Palliation of malignant ascitesJournal of Surgical Oncology, 2019
- Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort studyGynecologic Oncology, 2017
- Prognosis of untreated hepatocellular carcinomaHepatology, 2014
- Malignant ascites: pathophysiology and treatmentInternational Journal of Clinical Oncology, 2012
- Malignant ascites: Systematic review and guideline for treatmentEuropean Journal of Cancer, 2006